Biomea Fusion (BMEA) Set to Release Quarterly Earnings on Tuesday

Biomea Fusion (NASDAQ:BMEA) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

Biomea Fusion (NASDAQ:BMEA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.10. On average, analysts expect Biomea Fusion to post ($0.65) EPS for the current fiscal year and ($0.71) EPS for the next fiscal year.

Biomea Fusion Stock Performance

Shares of NASDAQ BMEA opened at $0.64 on Tuesday. The firm has a market capitalization of $46.07 million, a price-to-earnings ratio of -2.19 and a beta of -0.28. The stock has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.39. Biomea Fusion has a 52-week low of $0.55 and a 52-week high of $2.24.

Analyst Upgrades and Downgrades

BMEA has been the subject of a number of research analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Biomea Fusion in a research report on Wednesday, September 30th. Wall Street Zen downgraded Biomea Fusion from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Biomea Fusion in a research report on Wednesday, October 14th. Brookline Capital Markets began coverage on Biomea Fusion in a research note on Wednesday, October 7th. They set a “buy” rating on the stock. Finally, Citizens Jmp restated a “market outperform” rating and issued a $7.00 price objective on shares of Biomea Fusion in a report on Wednesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.60.

About Biomea Fusion

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to engage disease-relevant protein targets.

Biomea’s lead investigational product is BMF-219, an oral, selective covalent inhibitor of menin. The company has evaluated BMF-219 in clinical studies for certain hematologic malignancies and solid tumors, including acute leukemias and multiple myeloma, and has also investigated its potential in metabolic diseases such as type 2 diabetes.